← All stocks

Latigo Biotherapeutics, Inc.

LTGO Net buying

CIK 0002056611 #2325 in the set updated 17 Sep 2026

Bought (120 mo)

$5.04M

out of their own pocket, the only kind of buying there is

Sold (120 mo)

$0.00

$0.00 on a plan · $0.00 straight out of an exercise

Sold at will

$0.00

0 of 0 sales

Net

+$5.04M

+$5.04M against sales at will

By person

6 insiders · 2 transactions

Insider

Role

Bought

Sold

Net

Holding

Worth

Change

Foresite Capital Management V, LLC entity

10% owner

$2.52M (1)

—

+$2.52M

3,414,544

$61.46M

—

Tananbaum James B.

Director

$2.52M (1)

—

+$2.52M

3,414,544

$61.46M

—

5AM Ventures VI, L.P. entity

10% owner

—

2,350,419

$42.31M

—

SEIDENBERG BETH C

Director

—

2,094,813

$37.71M

—

Westlake BioPartners Fund I, L.P. entity

10% owner

—

2,094,813

$37.71M

—

Sanofi

10% owner

—

672,788

$12.11M

+6,727,780%

No percentages here. Latigo Biotherapeutics, Inc. reports its share count only per share class, which the XBRL frames API does not carry.

Individual transactions

Nothing of that kind in this period.

What was left out

Form 4 filings counted 7

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 3

Sales on a Rule 10b5-1 plan 0

Sales straight out of an exercise 0

Sales at will 0

Transactions with no price 0

Shares from compensation/vesting 51,472,006

History held since 10 Aug 2026